Table 1 Clinical features and management outcomes of patients with ICI-related colitis. p value in column denotes differences between Group A, Group B and Group C by Kruskal−Wallis test for continuous data or chi-square test for categorical data.
From: Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
Group A: Ipilimumab monotherapy (n = 189) | Group B: Anti-PD-1 monotherapy (n = 728) | Group C: Combination ipilimumab and nivolumab (n = 157) | p value | Total | |
|---|---|---|---|---|---|
Patients with colitis (n, %) | 42 (22) | 41 (6) | 51 (32) | 2 × 10−23 | 134 (13) |
Onset of colitis since start of treatment (median days, interquartile range) | 64 (35–91) | 69 (29–150) | 40 (20–65)††, ‡ | <0.05 | 60 (28–88) |
Median age of colitis patients (years, interquartile range) | 67 (57–76) | 70 (58–76) | 63 (56–68) | <0.05 | 66 (57–72) |
Male sex in colitis patients (n, %) | 28 (67) | 23 (56) | 30 (59) | 0.95 | 81 (60) |
Colitis patients with hospital admission | 17 (40) | 19 (46) | 38 (75) | <0.0001 | 64 (48) |
Days to first admission from onset of diarrhoea (Median, interquartile range) | 4 (3–6) | 3 (0–5) | 5 (3–10)†† | <0.05 | 4 (3–7) |
Time from colitis onset to endoscopy (Median, interquartile range) | 12 (4–18) | ||||
Length of first hospital stay in days for patients requiring admission (median, interquartile range) | 4 (3–8) | 5 (3–8) | 6 (3–10) | 0.37 | 5 (3–9) |
Treatment | |||||
Any steroids (n, %) | 38 (90) | 29 (71) | 50 (98) | <0.001 | 117 (87) |
IV steroids (n, %) | 12 (29) | 14 (34) | 38 (75) | <0.001 | 58 (43) |
Days of IV steroids in those receiving (median, interquartile range) | 3 (2–4) | 5 (3–8) | 4 (3–6) | 0.16 | 4 (3–6) |
Total days on any steroids (median, interquartile range) | 59 (51–92) | 60 (31–102) | 66 (49–117) | 0.53 | 62 (47–100) |
Infliximab (n, % total) | 4 (10) | 8 (20) | 17 (33) | <0.01 | 29 (22) |
Colectomy (n, % total) | 2 (5) | 0 (0) | 1 (2) | 0.35 | 3 (2) |
